{"name":"NEUROVALENS LIMITED","company_number":"NI617853","status":"Active","type":"Private Limited Company","incorporated":"2013-04-12","dissolved":null,"registered_office":"8 Carmagrim Road, Portglenone, Ballymena, County Antrim, Northern Ireland, BT44 8BP","postcode":"BT44 8BP","sic_codes":[{"code":27900,"description":"Manufacture of other electrical equipment"},{"code":72110,"description":"Research and experimental development on biotechnology"},{"code":86900,"description":"Other human health activities"}],"principal_activity":null,"previous_names":[],"warnings":[],"accounts":{"category":"Total Exemption Full","year_end":"31 December","last_made_up_to":"2025-12-31","next_due":"2027-09-30"},"employees":{"count":23,"accounts_date":"2025-12-31"},"financials":[{"financial_date":"2025-12-31","net_assets":2113748,"cash":2906112,"average_employees":23},{"financial_date":"2024-12-31","net_assets":-9054066,"cash":1073926,"average_employees":25},{"financial_date":"2023-12-31","net_assets":-5947625,"cash":1300305,"average_employees":25},{"financial_date":"2022-12-31","net_assets":-3232415,"cash":2871749},{"financial_date":"2021-12-31","net_assets":-1513063,"cash":4571618}],"officers":{"current":7,"resigned":7,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Neurovalens Limited holds a strategically valuable position in non-invasive neurostimulation for insomnia, with FDA clearance providing a meaningful competitive moat in a market ripe for non-pharmacological alternatives. However, the company faces an acute financial inflection point—having accumulated £15M in losses with less than 12 months of cash runway, it is entirely dependent on a £4M fundraising expected in May 2025 to sustain operations through 2027. The transition from R&D to commercial sales, which began in October 2024, must demonstrate rapid revenue traction or the company risks value destruction before its technology's market potential can be realised.","website":"https://neurovalens.com/","links":{"page":"https://www.companiesintheuk.co.uk/ltd/neurovalens","people":"https://www.companiesintheuk.co.uk/company/neurovalens/people","filing_history":"https://www.companiesintheuk.co.uk/company/neurovalens/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/NI617853","financials":"https://www.companiesintheuk.co.uk/company/neurovalens/financial","control":"https://www.companiesintheuk.co.uk/company/neurovalens/control","charges":"https://www.companiesintheuk.co.uk/company/neurovalens/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/neurovalens/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/neurovalens"}